Cardiac troponin I: is it a marker to detect cardiotoxicity in children treated with doxorubicin?

Turk J Pediatr. Jan-Mar 2005;47(1):17-22.


Doxorubicin has been used in the the treatment of malignant tumors in children. Its use is limited by cardiotoxic effects beyond a cumulative dose of 450 mg/m2. To detect cardiotoxicity at an early stage and identify patients at risk for development of cardiotoxicity are matters of concern. Recently, cardiac troponin I (cTnI) has been reported to be useful for detecting minor myocardial damage. In the present study, we investigated whether cumulative doxorubicin-related myocardial cell damage can potentially increase cTnI levels above the expected values in 22 patients treated with cumulative doxorubicin doses of 120 to 450 mg/m2. Impaired cardiac functions were found in three patients by echocardiography, but serum CTnI levels were within the ranges expected in healthy individuals both in patients with cumulative doxorubicin doses > or = 400 mg/m2 and in patients with disturbed cardiac functions. We found no relationship between serum cTnI, cumulative dose of doxorubicin, and echocardiographical findings.

Publication types

  • Clinical Trial

MeSH terms

  • Adolescent
  • Adult
  • Antibiotics, Antineoplastic / administration & dosage
  • Antibiotics, Antineoplastic / adverse effects
  • Antibiotics, Antineoplastic / therapeutic use
  • Biomarkers / blood*
  • Bone Neoplasms / drug therapy
  • Child
  • Dose-Response Relationship, Drug
  • Doxorubicin / administration & dosage
  • Doxorubicin / adverse effects*
  • Doxorubicin / therapeutic use
  • Echocardiography
  • Electrocardiography
  • Female
  • Heart / drug effects
  • Heart / physiopathology
  • Humans
  • Male
  • Osteosarcoma / drug therapy*
  • Predictive Value of Tests
  • Troponin I / blood*


  • Antibiotics, Antineoplastic
  • Biomarkers
  • Troponin I
  • Doxorubicin